On Invalid Date, Alnylam Pharmaceuticals (NASDAQ: ALNY) reported Q4 2023 earnings per share (EPS) of -$1.09, up 35.12% year over year. Total Alnylam Pharmaceuticals earnings for the quarter were -$137.87 million. In the same quarter last year, Alnylam Pharmaceuticals's earnings per share (EPS) was -$1.68.
As of Q2 2024, Alnylam Pharmaceuticals's earnings has grown year over year. Alnylam Pharmaceuticals's earnings in the past year totalled -$440.24 million.
What is ALNY's earnings date?
Alnylam Pharmaceuticals's earnings date is Invalid Date. Add ALNY to your watchlist to be reminded of ALNY's next earnings announcement.
What was ALNY's revenue last quarter?
On Invalid Date, Alnylam Pharmaceuticals (NASDAQ: ALNY) reported Q4 2023 revenue of $439.72 million up 31.25% year over year. In the same quarter last year, Alnylam Pharmaceuticals's revenue was $335.04 million.
What was ALNY's revenue growth in the past year?
As of Q2 2024, Alnylam Pharmaceuticals's revenue has grown 76.23% year over year. This is 69.5 percentage points lower than the US Biotechnology industry revenue growth rate of 145.73%. Alnylam Pharmaceuticals's revenue in the past year totalled $1.83 billion.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.